Oregon Health and Science University
The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by: * Echocardiographic measurements of pulmonary hypertension * Change in 6-minute walk distance (6MWD) * Change in categorization of disease (World Health Organization Functional Class, WHO FC) * Quality of life improvements Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities: * Physical exam * Labs including drug screening * Pulmonary function testing (PFT) * Exercise testing (6MWD) * Echocardiography * Right heart catheterization (RHC) * Questionnaires related to their disease Participants will be in the study for about six months.
Inclusion Criteria: * Age ≥ 18 years * Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis * Symptomatic PAH classified as WHO FC II or III * Diagnosis of PAH within 12 months of screening and on stable doses of…
Sotatercept given in coordination with addiction medicine services